Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000792823 | SCV000932144 | uncertain significance | Polyglucosan body myopathy type 1 | 2022-10-18 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with glutamic acid, which is acidic and polar, at codon 233 of the RBCK1 protein (p.Asp233Glu). This variant is present in population databases (rs746724862, gnomAD 0.02%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with RBCK1-related conditions. ClinVar contains an entry for this variant (Variation ID: 639908). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on RBCK1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002535879 | SCV003660359 | uncertain significance | Inborn genetic diseases | 2022-12-12 | criteria provided, single submitter | clinical testing | The c.699C>G (p.D233E) alteration is located in exon 6 (coding exon 6) of the RBCK1 gene. This alteration results from a C to G substitution at nucleotide position 699, causing the aspartic acid (D) at amino acid position 233 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |